
Please try another search
HitGen Inc. operates as a drug discovery research platform for small molecules and nucleic acid drugs in China and internationally. Its technology platform includes DNA-encoded library technology; fragment-based drug discovery and structure-based drug design technologies; emerging technology platforms for synthetic therapeutic oligonucleotide technology; and targeted protein degradation technology. The company’s product pipeline includes HG146, a selective HDAC inhibitor for multiple myeloma and solid tumor; HG030, a second generation NTRK/ROS1 inhibitor tablet for solid tumor; HG153 a Menin-MLL tablet; HG248; and HG 381, an immune-oncology agonist for cancer, as well as HGP0508, a small molecule for anti-inflammatory therapeutics for inflammation; HGP1069, a ROCK2 inhibitor eye drop. Further, it offers target validation, hit identification, hit-to-lead optimization, lead optimization, preclinical studies and IND, clinical development, and integrated drug discovery services. Additionally, the company focus on oncology and immuno-oncology, inflammatory and autoimmune diseases, ophthalmology, infectious, metabolic, and cardiovascular diseases. HitGen Inc. was founded in 2012 and is based in Chengdu, China.
Name | Age | Since | Title |
---|---|---|---|
Li Jin | 62 | 2019 | Chairman & GM |
Jianguo Li | 64 | 2019 | Director |
Li Suibo | 64 | 2022 | Director |
Yunpei Guo | 78 | 2022 | Independent Director |
Lu Kai | 72 | 2019 | Vice Chairman |
Lin Wang | 57 | 2019 | Director |
Jianming Wang | 43 | 2023 | Director |
Haizong Yu | 61 | 2019 | Independent Director |
Xue Junfu | 58 | 2022 | Independent Director |
Chenhui Xu | 59 | 2019 | Chairman of the Supervisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review